PatentAug 12, 2026, 09:07 AM
SciSparc Subsidiary NeuroThera Labs Gets Japanese Patent
AI Summary
SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs Inc., has been granted a Japanese patent. The patent covers a proprietary pharmacological combination designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies, potentially allowing for lower effective dosing and reduced side effects. This milestone strengthens NeuroThera's intellectual property portfolio and supports its global therapeutic innovation efforts.
Key Highlights
- SciSparc's subsidiary NeuroThera Labs received a Japanese patent.
- Patent is for a pharmacological combination titled "Compositions and Methods for Potentiating Derivatives of 4-Aminophenols."
- Covers combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines.
- Designed to enhance analgesic and antipyretic performance of 4-aminophenol-based therapies.
- Aims to enable lower effective dosing and mitigate dose-related side-effect concerns.
- Strengthens NeuroThera's intellectual property portfolio for combination-therapy platforms.
Price Impact
More from SPRC